Previous 10 |
SEATTLE, Feb. 07, 2019 (GLOBE NEWSWIRE) -- , February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today updated the status o...
SEATTLE, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has provided suggested changes to the dra...
SAN FRANSICO, CA / ACCESSWIRE / January 30, 2019 / Vista Partners ("Vista") has published January 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Global Expansion Slows." Vista's monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Ene...
SEATTLE, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders: To Our Valued Shareholders: I begin this letter with a sense of great pride about our accomplishments at...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...